Masaki Kaibori

44PUBLICATIONS
83CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyPredictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Jul 28, 2026
Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer.

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

|Apr 12, 2026
Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

Hisashi Kosaka, Rie Sugimoto, Masahiko Kinoshita

Pageof 8

Frequent Collaborators

39 joint publications

Masaki Kaibori

28 joint publications

Atsushi Hiraoka

26 joint publications

Takeshi Hatanaka

26 joint publications

Hidenori Toyoda